Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
0.500
-0.091 (-15.33%)
Mar 9, 2026, 1:56 PM EDT - Market open
Jaguar Health Employees
Jaguar Health had 49 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
49
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$240,510
Profits / Employee
-$822,306
Market Cap
2.27M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Scinai Immunotherapeutics | 31 |
| Calidi Biotherapeutics | 28 |
| Azitra | 12 |
| Dermata Therapeutics | 8 |
| Artelo Biosciences | 7 |
| Enveric Biosciences | 6 |
| 60 Degrees Pharmaceuticals | 3 |
| PMGC Holdings | 3 |
JAGX News
- 5 hours ago - Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants - Accesswire
- 6 days ago - Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1 - Accesswire
- 7 days ago - Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend - Accesswire
- 19 days ago - Jaguar Health Announces a Special One-time Stock Dividend - Accesswire
- 6 weeks ago - Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi - Accesswire
- 7 weeks ago - Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts - Accesswire
- 2 months ago - Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million - Accesswire
- 2 months ago - Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication - Accesswire